. . "withdrawn"@en . . "Humans and other mammals"@en . "Urokinase acts on the endogenous fibrinolytic system. It cleaves the Arg-Val bond in plasminogen to produce active plasmin. Plasmin degrades fibrin clots as well as fibrinogen and other plasma proteins."@en . "Urokinase"@en . "Low molecular weight form of human urokinase, that consists of an A chain of 2,000 daltons linked by a sulfhydryl bond to a B chain of 30,400 daltons. Recombinant urokinase plasminogen activator"@en . . . "# Housley C: Contract purchasing means a buyer's market. Dimens Health Serv. 1976 Apr;53(4):16, 19-20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/5328"@en . . "investigational"@en . . . . . "Urokinase administered by intravenous infusion is rapidly cleared by the liver. Small fractions of the administered dose are excreted in bile and urine"@en . . "U-plasminogen activator"@en . " "@en . . "Urokinase-type plasminogen activator precursor"@en . . . . . "12 minutes. Small fractions of the administered dose are excreted in bile and urine"@en . . . . "9039-53-6"@en . "approved"@en . "Koji Sasaki, Yasukazu Harada, \"Urokinase preparation for oral administration.\" U.S. Patent US4258030, issued November, 1975."@en . . . . . "Urokinase can be used for the treatment of pulminary embolism, coronary artery thrombosis, IV catheter clearance, and venous and arterial blood clots."@en . "uPA"@en .